A study connects aloperine binding and VPS34 lactylation to disrupted endosomal trafficking in lung cancer cells. Patient-derived organoids provided additional evidence of a stronger response to aloperine plus cisplatin than to either agent alone.
Researchers at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, and collaborating institutions investigated aloperine in non-small-cell lung cancer (NSCLC). Their focus was methuosis, a nonapoptotic form of cell death associated with dysregulated macropinocytosis and accumulation of large cytoplasmic vacuoles. Mechanistic work in human A549 and H1299 cells was followed by combination testing in patient-derived organoids.
In 24-hour Cell Counting Kit-8 (CCK-8) assays, aloperine’s half-maximal inhibitory concentrations were 189 µM in A549 and 182 µM in H1299 cells. The vacuoles took up dextran and showed late-endosomal features, while fusion with lysosomes was impaired. Interventions targeting macropinocytosis or the vacuolar process reduced the phenotype and restored viability-related signals. The tested apoptosis, autophagy and ferroptosis inhibitors did not provide the same rescue.
The lysosomal measurements were not uniform: aloperine did not significantly alter the measured pH, but it reduced proteolytic activity and impaired endolysosome-dependent EGFR degradation. These results implicate trafficking and degradation rather than a single change affecting every lysosomal function.
Protein-stability assays, mass spectrometry, thermal-shift measurements and surface plasmon resonance supported direct binding to VPS34. The purified-protein binding experiment gave a dissociation constant of 3.59 µM. Replacing Ile760 with valine disrupted the interaction and attenuated the cellular phenotype. The binding constant and the cellular inhibitory concentrations describe different assays.
Aloperine strengthened the VPS34–TIP60 interaction and increased VPS34 lactylation at K356 and K781. A double-site mutant attenuated lactylation-associated damage and vacuolization. Total VPS34 expression did not show the corresponding increase, directing attention to modification and function rather than protein abundance.
A separate comparison of six paired tumor and adjacent-tissue specimens found higher lactate in the tumors. Adding lactate to the cell experiments enhanced aloperine-associated lactylation, vacuolization and loss of viability-related activity. This suggests that the metabolic setting can influence the response; the tissue measurement and organoid combination experiment are distinct parts of the evidence.
Reduced phosphatidylinositol 3-phosphate [PI(3)P] was accompanied by less recruitment of Armus to endosomal membranes and accumulation of active Rab7-GTP. Rescue experiments involving PI(3)P and Rab7 supported a role for this axis in disrupted endolysosomal trafficking. These target and mutation experiments were conducted mainly in cell lines and protein systems.
The NSCLC organoids were derived from fresh surgical tissue donated by adults at Wuhan Union Hospital. The team compared aloperine, cisplatin and the combination through growth, morphology, CCK-8 activity and protein measurements. This provided a three-dimensional, patient-tissue-derived setting in which to test whether the combination response extended beyond the cell lines.
Combination treatment restrained growth, disrupted clustered organoid structure and reduced CCK-8 activity more strongly than either single agent. Methuosis-related protein changes were also greater than with aloperine alone. In parallel A549 experiments, the combination increased vacuolization and apoptotic markers, supporting contributions from both processes.
The main paper does not specify the number of independent organoid donors or provide patient-stratified responses. The experiment supports a model-based combination effect; how consistently it occurs across patient tumors remains unresolved.
Separate mouse tumor experiments showed stronger growth suppression with the combination and assessed body weight, histology and selected liver and kidney biochemical measures. No obvious corresponding injury was reported under the tested regimen. These were animal observations; the study did not evaluate safety or efficacy in people.
Tumors bearing the K356/K781 double-site VPS34 mutant were less responsive to aloperine-mediated growth inhibition and associated molecular changes. This agreed with the cellular perturbation results and supported the proposed lactylation dependence, without establishing its prevalence across patient tumors.
The human-model contribution is the connection between target perturbation, cellular function and a treatment response in patient-derived tumor material. Mutational experiments strengthen the mechanism, while organoids add evidence for the combination in a different model context. Cellular concentrations, organoid exposure conditions and achievable human exposure remain separate questions for further translational evaluation.
Single-cell analysis identified conserved epithelial programs associated with survival and resistance. Patient-derived organoid experiments then shifted platinum responses through SERCA2 activation or CCDC6 inhibition.
Assembloids from six patients reproduced their corresponding immunotherapy-response patterns. Component exchange and perturbations connected tumor WNT2B, fibroblast activin A and stem-like CD8 T cells, with low stromal LRP6 linked to resistance.
